Bayer

688 articles with Bayer

• Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual Summit

  6/15/2020

  Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi ® Versus Adynovate ® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual Summit WHIPPANY, N.J.--( BUSINESS WIRE )-- Bayer announced today it will present new data highlighting the results from the first head-to-head study directly comparing the pharmacokinetic (PK) profiles of two extended half-life (EHL) recombinant factor VIII (FVIII) therapies, Jivi ® (

• Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction

  6/15/2020

  Bayer announced today the initiation of the FINEARTS-HF study, a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of investigational finer

• Fungicide Application at Feekes 10.5.1 Helps Increase Yield Potential

  6/11/2020

  Applying Prosaro® fungicide at early flowering helps protect grain quality, yield and profitability in cereal crops

• Celmatix Achieves First Milestone in Women’s Health Drug Discovery Alliance With Evotec

  6/3/2020

  Evotec licenses novel polycystic ovary syndrome target identified by Celmatix through its Reproductive Atlas™ platform to Bayer

• Bayer Launches the Second Annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Encourage and Recognize Innovation in Pulmonary Research

  6/1/2020

  Bayer Launches the Second Annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Encourage and Recognize Innovation in Pulmonary Research Awards program underscores the importance of critical clinical research to deepen understanding of pulmonary disease to help improve patient outcomes WHIPPANY, N.J.--( BUSINESS WIRE )-- Bayer announced today the launch of the second annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to support cl

• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

• The Efficacy of Vitrakvi® (larotrectinib) Further Demonstrated High Response Rates and Duration of Response in an Updated Analysis and New Quality of Life Data to Be Presented at ASCO

  5/29/2020

  The Efficacy of Vitrakvi ® (larotrectinib) Further Demonstrated High Response Rates and Duration of Response in an Updated Analysis and New Quality of Life Data to Be Presented at ASCO Intended for U.S. Media Only 71 percent overall response rate (ORR) per investigator assessment and median duration of response of 35.2 months shown in expanded data set of 116 adult patients with TRK fusion cancer 1 Among patients with brain metastases, ORR was

• 

  ASCO 2020 Preview: A Peek at Some Presentations and Topics at this Year’s Virtual Con

  5/29/2020

  Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.

• Bayer Fund Awards Millions of Dollars in Grants to Help Thousands of Americans, During the COVID-19 Pandemic

  5/18/2020

  Bayer Fund, a philanthropic arm of life sciences company Bayer, today awarded more than $4 million in grants to 250 charities and non-profit organizations throughout the United States.

• 

  Clinical Catch-Up: May 11-15

  5/18/2020

  Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.

• Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib)

  5/14/2020

  Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI ® (larotrectinib) Collaboration will focus on development of a companion diagnostic (CDx) for Vitrakvi ® , the first-in-class tyrosine kinase (TRK) inhibitor approved in the U.S. and Europe for adult and pediatric patients with TRK fusion cancer across all solid tumors. Vitrakvi has the largest and longest-term data set

• NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy Showed a Statistically Significant Improvement in Overall Survival with Proven Efficacy and Tolerability in Men with Non-Metastatic Castration-Resistant Prostate Cancer

  5/13/2020

  NUBEQA reduced the risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) compared to placebo in its secondary endpoint of overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC)

• Specifica Announces Antibody Discovery Platform Transfer to Bayer

  5/12/2020

  Company's Generation 3 Antibody Platform Delivers High-Affinity, Drug-Like Antibody Candidates Well Designed to Facilitate the Development of High-Quality Therapeutics

• Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program

  5/11/2020

  Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)

• 

  Biopharma Update on the Novel Coronavirus: May 11

  5/11/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.

• Bayer and NeoGenomics Launch the Test4TRK™ Program to Provide Genomic Cancer Testing at No Cost for People Living with Advanced Thyroid and Colorectal Cancers

  5/5/2020

  Bayer to cover testing costs for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) The results of a genomic cancer test can help healthcare providers determine appropriate treatment plans for people with an NTRK gene fusion NTRK gene fusions can drive tumor growth and are more common in MSI-H mCRC and RAI-R DTC cases than other subt

• Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detection

  4/30/2020

  The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world's first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• 

  Q1 Reports: Biogen, Merck and Other Biopharma Companies Note Ups and Downs Amid COVID-19 Pandemic

  4/28/2020

  Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted.

• Bayer to Highlight Clinical Data on Vitrakvi® (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting

  4/23/2020

  Additional analyses from clinical trials may further aid in identifying the appropriate patients for Vitrakvi® (larotrectinib), including a presentation on patient outcomes by prior therapy and performance status Featured research includes an oral presentation in the Plenary Session on efficacy and safety outcomes in patients with NTRK gene fusions or other alterations Structure and functional characterization of investigational sma

• 

  GlobalData Report: Top 20 Pharma Companies Lost $2.6 Trillion Market Cap in Q1

  4/23/2020

  The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.